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v-ErbA is a mutated variant of thyroid hormone receptor
(TRa/NR1A1) borne by the Avian Erythroblastosis virus
causing erythroleukemia. TRa is known to activate
transcription of specific genes in the presence of its cognate
ligand, T3 hormone, while in its absence it represses it. v-
ErbA is unable to bind ligand, and hence is thought to
contribute to leukemogenesis by actively repressing
erythroid-specific genes such as the carbonic anhydrase
II gene (CA II). In the prevailing model, v-ErbA occludes
liganded TR from binding to its cognate elements and
constitutively interacts with the corepressors NCoR/
SMRT. We previously identified a v-ErbA responsive
element (VRE) within a DNase I hypersensitive region
(HS2) located in the second intron of the CA II gene. We
now show that HS2 fulfils all the requirements for a
genuine enhancer that functions independent of its
orientation and position with a profound erythroid-specific
activity in normal erythroid progenitors (T2ECs) and in
leukemic erythroid cell lines. We find that the HS2
enhancer activity is governed by two adjacent GATA-
factor binding sites. v-ErbA as well as unliganded TR
prevent HS2 activity by nullifying the positive function of
factors bound to GATA-sites. However, v-ErbA, in
contrast to TR, does not convey active repression to
silence the transcriptional activity intrinsic to a hetero-
logous tk promoter. We propose that depending on the
sequence and context of the binding site, v-ErbA
contributes to leukomogenesis by occluding liganded TR
as well as unliganded TR thereby preventing activation or
repression, respectively. Oncogene (2001) 20, 775 – 787.
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Introduction
Malignant transformation of hematopoietic cells is
caused by the disturbance of a delicate balance between
proliferation and dierentiation. The correct function-
ing of members of the nuclear hormone receptor
superfamily is required to maintain homeostasis, and
to promote dierentiation of hematopoietic cells. Not
surprisingly, mutated, aberrant nuclear receptors are
found in many types of cancer and diseases (Wol,
1997; Goldhirsch and Gelber, 1996). Paradigms are
fusion proteins involving retinoic acid receptor
(RARa), PML-RARa, PLZF-RARa and NPM-RARa
that cause human acute promyelocytic leukemia (APL)
(review Warrell et al., 1993). v-ErbA is an oncogenic
version of chicken thyroid hormone receptor (TRa)
and is one of the two co-operating oncogenes of the
Avian erythroblastosis virus (AEV) which causes fatal
avian erythroleukemia (AEL) in chickens (for review
Beug et al., 1996; Stunnenberg et al., 1999). The second
oncogene of AEV is v-ErbB, which is a mutated
epidermal growth factor receptor (EGFR) with con-
stitutive tyrosine kinase activity. While v-ErbB alone
causes a partial dierentiation arrest and a delayed,
weak erythroleukemia, v-ErbA by itself transforms
erythroid progenitor in vitro (Gandrillon et al., 1989)
but induces disease in vivo only when suciently
overexpressed (Casini and Graf, 1995; for review Beug
et al., 1996). The transformation promoting activity of
v-ErbA is widely thought to lie in its ability to arrest
dierentiation of v-ErbB-expressing erythroblasts by
eectively silencing stage-specific erythroid genes such
as the carbonic anhydrase II gene (CA II) that are
otherwise activated by liganded TR (Pain et al., 1990;
Disela et al., 1991; Zenke et al., 1990).
TRa (NR1A1) (Nomenclature committee, 1999), acts
as a ligand-operated molecular switch; firstly, in the
absence of ligand, TR is proposed to repress transcrip-
tion via association with corepressors such as NCoR/
SMRT (Horlein et al., 1995; Chen and Evans, 1995).
The corepressors, in turn, recruit histone deacetylase
(HDAC)-containing complex(es) that stabilise(s) re-
pressive, ‘closed’ chromatin structure to assure ecient
silencing of downstream genes (Heinzel et al., 1997;
Wong et al., 1998). Second, upon ligand binding, the
receptor undergoes a conformational change that
causes dissociation of the corepressor complex(es) and
permits subsequent association of coactivator com-
plexes such as p300/CBP, SRC and TRAP/SMCC to
activate transcription (Ogryzko et al., 1996; Bannister
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and Kouzarides 1996; for review Glass and Rosenfeld,
2000). Hence, the ability of v-ErbA to transform
erythroid progenitors can be attributed to its un-
liganded ‘mode’ displaying a constitutive repressive
activity by antagonising T3-mediated transcriptional
activation (Damm et al., 1989; Sap et al., 1989; Horlein
et al., 1995; Chen and Evans, 1995; for review
Stunnenberg et al., 1999; Thormeyer and Baniahmad,
1999). The fact that many of the mutations in v-ErbA
abolish activation functions present in genuine TRa
(NR1A1) (Barettino et al., 1994) is consistent with the
occlusion/corepressor model. Although attractive, this
model awaits in vivo verification; thus far, supporting
data have been obtained almost exclusively from
transient transfection assays, two-hybrid assays and in
vitro GST-pull down experiments. One observation in
particular is dicult to reconcile with this model. v-
ErbA, as compared to TR, shows lower anity and
altered DNA specificity for classical thyroid responsive
elements (TREs) mainly due to a mutation in the
DNA-recognition helix (P-box) (Judelson and Privals-
ky, 1996; Subauste and Koenig, 1995; Wahlstrom et
al., 1996). Reversion of this mutation restores wild type
(TR) DNA binding anity. However, rather than
acting as a superoncogene (due to increased DNA
binding properties), the P-box-reverted v-ErbA variant
has lost the ability to transform erythroid cells (Nelson
et al., 1994; Sharif and Privalsky, 1991; Bauer et al.,
1997). These observations imply that v-ErbA does not
merely function as a constitutive unliganded TR;
moreover, the set for v-ErbA binding sites appears to
be distinct from or only partially overlapping with that
of TR.
In a previous study, we identified a DNase I
hypersensitive site (HS2) in the second intron of the
chicken carbonic anhydrase II (CA II) gene (Ciana et
al., 1998). CA II is a direct target gene of v-ErbA and
deregulation of CA II transcription partially accounts
for the v-ErbA induced phenotype (Fuerstenberg et al.,
1992). Our data suggested that HS2 might act as an
enhancer. We showed that the v-ErbA oncoprotein
bound to a v-ErbA responsive element (VRE), located
within the HS2, prevented the activity of the enhancer.
Here, we report on a detailed analysis of the CA II-
HS2 enhancer that provides insight into the mechanism
by which v-ErbA aects transcription of erythroid-
specific genes, therefore blocking dierentiation during
lineage commitment. Using transient transfection
assays in AEV-transformed erythroid progenitor
(HD3) cells we have assessed cis-acting sequences
governing the CA II-HS2 function and have defined
HS2 as a true tissue-specific enhancer that acts
independent of its position and orientation with respect
to the promoter. Furthermore, the activation of the
HS2 enhancer is dependent on factors bound to
GATA-protein binding sites and v-ErbA acts by
quenching their activity. Our study reinforces that v-
ErbA acts as a dominant negative TR by occluding the
VRE and ablating the T3-mediated activation of
CA II. However, when the HS2-VRE is linked to the
tk promoter, v-ErbA, but not unliganded TR, is
inecient in repressing the transcriptional activity
intrinsic to the tk promoter. These data suggest that
v-ErbA exerts only part of the full complement of
negative, repressive activity intrinsic to TR.
Results
Carbonic anhydrase II HS2 region acts as a true enhancer
Using DNase I hypersensitivity mapping, we have
previously identified a novel v-ErbA responsive
element (VRE), comprised of two half-sites in a direct
repeat configuration spaced by four nucleotides
(DR4), located in a hypersensitive site in the second
intron of carbonic anhydrase II (CA II) gene, termed
HS2 (Ciana et al., 1998 and Figure 1a). Transient
transfection assays in AEV-transformed HD3 cells
using a HS2-containing reporter (HS2-tk) showed that
HS2 does not confer any transcriptional activity to the
promoter. However, mutation of the first half-site of
the VRE (M1-HS2-tk), that abolished v-ErbA binding
resulted in a 30-fold enhancement of transcription
(Ciana et al., 1998 and Figure 1b). These and other
observations suggested that the HS2 region likely
functions as an enhancer which is repressed by v-
ErbA.
Operationally, enhancers are defined as cis-acting
sequences that activate transcription of promoters in a
position- and orientation-independent manner. To test
orientation (in)dependency we first placed the M1-HS2
element in both orientations (+ and 7) upstream of
its cognate CA II promoter (7180 to +51) yielding
M1-HS2(+)-CAII and M1-HS2(7)-CAII constructs,
respectively. Transient transfection assays in HD3 cells
showed that M1-HS2 boosted the level of transcription
via the CA II promoter to the same extent as observed
for the tk promoter reporter (Figure 1b). Moreover,
the HS2 enhancer acted in both orientations. As
expected, the HS2 fragment with the wild type VRE
did not activate transcription from the CA II promoter
(data not shown). Similar results were obtained with
M1-HS2 as an enhancer in combination with a longer
CA II promoter fragment (1.4 kb, position 71362 to
+51) (data not shown).
Since the natural position of the HS2 enhancer in
CA II gene is in the second intron (Figure 1a), we
tested whether HS2 could enhance transcription from a
position downstream of the CA II promoter. Tran-
scription of the resulting constructs (CAII-M1-HS2)
was boosted 11 – 16-fold (Figure 1c). Analogously, the
M1-HS2 fragment placed in either orientation down-
stream of the tk promoter also enhanced transcription
but to a lesser extent (data not shown).
Taken together, these results unambiguously show
that HS2 acts both upstream and downstream of its
natural CA II promoter as well as the heterologous tk
promoter in an orientation independent fashion and is
therefore a bona fide enhancer. Furthermore, v-ErbA
appears to impair the activity of the potent HS2
enhancer.
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Delineation of the HS2 enhancer
To dissect the molecular mechanism of repression by
the v-ErbA oncoprotein, we set out to identify cis-
acting sequences that are important for the observed
HS2 enhancer activity. Given the presence of high
levels of v-ErbA in HD3 cells, fragments spanning the
HS2 and carrying the wild type VRE sequence do not
display enhancer activity (Ciana et al., 1998 and Figure
1b). Therefore, we constructed a series of 5’ and 3’
deletion mutants within the context of M1(883 – 1175)-
tk, a 288 bp fragment encompassing the entire HS2, to
screen for cis-acting sequences (Figure 2). This
construct showed enhancer activity comparable to that
of the previously analysed, 135 bp containing M1-HS2-
tk reporter. Two deletions from the 5’ end of the
Figure 1 The HS2 fragment functions as a true enhancer (a) Schematic representation of the CA II locus with exons 1 – 4 (black
boxes) and DNase I hypersensitive sites HS1 and HS2 (open boxes). The insert details the 288 bp (RsaI –RsaI) fragment with AluI
site defining the 3’ boundary of the 135 bp fragment used in most of the following experiments. GI, GII and GIII indicate position
of GATA-sites that were mutated and M1, M2 and M3 show the mutated receptor-half-sites. The VRE sequence is boxed. Letters
below the sequence indicate the substitution mutations in the various HS2 constructs. (b) Transient transfection assays in HD3 cells
with CA II promoter reporter constructs carrying the 135 bp M1-HS2 enhancer fragment in both orientations. The values represent
the mean value of the relative chloramphenicol acetyltransferase (CAT) activity, as normalized by luciferase values of the internal
control, of at least three experiments, with error bars shown. Transcriptional activity of tk-CAT construct is arbitrarily set to 1. (c)
Transfection assays in HD3 cells with reporters containing the M1-HS2 fragment downstream of the CA II promoter as indicated.
Transcriptional activity of CA II reporter is set to 1
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M1(883 – 1175)-tk fragment significantly reduced the
HS2 activity (Figure 2), while further deletion includ-
ing the VRE (plasmid HS2(979 – 1175)-tk) resulted in
abolishment of the enhancer activity.
Analysis of a 3’ deletion mutant of M1-HS2-tk (up
to position 7983) revealed a transcriptional activity
similar to M1-HS2-tk, while further 3’ deletion
including the VRE (up to position 7958) resulted in
slightly lower levels of transcription. Taken together,
our data show that sequences critical for the enhancer
activity are located mostly upstream of the VRE. For
reasons of consistency, the 135 bp HS2 region used in
our previous study (Ciana et al., 1998), which exhibits
the full enhancer activity in HD3 cells, was used in the
remainder of the experiments.
HS2 is an erythroid-specific enhancer
To assess whether HS2 acts as a ubiquitous or cell type-
specific enhancer we performed transfection experi-
ments using the HS2-tk and M1-HS2-tk reporters in a
number of dierent erythroid and non-erythroid cells
(Figure 3). In normal, untransformed, TGFa/TGFb-
induced chicken Erythroid Cells, T2EC (Gandrillon et
al., 1999), in mouse erythroleukemia (MEL) cells as well
as in human chronic erythroleukemia cell line K562,
HS2 boosted transcription seven- and 20-fold, respec-
tively. In T2ECs and MEL, the mutated M1-HS2
enhancer displayed higher transcriptional activity as
compared to the wild type HS2 (13- and 20-fold,
respectively) whereas in K562, the activity of the M1-
HS2-tk was twofold reduced. The higher level of
transcription obtained with M1-HS2 as compared to
the parental HS2 in T2ECs and MEL cells suggested
that the introduced mutations might have disrupted a
binding site for a cellular repressor distinct from v-
ErbA. The HS2(883 – 958)-tk reporter in which the VRE
and surrounding sequences were deleted displayed a
much higher activity in T2ECs as compared to M1-
HS2- and HS2-tk. This would suggest that the M1
mutation of the consensus nuclear receptor half-site did
not (fully) abolish repression mediated by sequences in
the 958 – 1020 region. In MEL cells, however, the
HS2(883 – 958) enhancer fragment displayed transacti-
vation activity similar to HS2. Because the HS2(979 –
1175)-tk reporter did not display transcriptional activa-
tion in MEL cells (data not shown), it seems likely that
the M1 mutation had fortuitously created a binding site
for a weak activator present in MEL cells. In contrast,
in K562 the HS2(883 – 958) and the M1-HS2 enhancers
were equally active but reduced as compared to the
parental HS2 suggesting that the HS2 enhancer may be
activated by an endogenous nuclear receptor. Neither
the parental nor the variants of the HS2 enhancer
displayed transcriptional activity when transfected in
the non-erythroid chicken embryonic fibroblasts (CEF)
and mouse fibroblasts (L) cells (Figure 3). Taken
together our data suggest that the HS2 enhancer activity
is confined to erythroid cells. The dierent transcrip-
tional activities of HS2 and M1-HS2 in the various cells
types appears to be dependent on the dierentiation
stage of the erythroid cells or on species specificity.
GATA-factors binding sites contribute to the HS2
enhancer activity
In HD3 cells the obtained overall activity of the HS2
enhancer probably is the net result of repression
Figure 2 Delineation of the intronic enhancer region HS2 of the CA II gene. Assays of CAT expression of HD3 cells transfected
with the indicated fragments of HS2 enhancer cloned in front of tk promoter. Transcription is expressed relative to tk promoter
alone
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instigated from the VRE and enhancement from
positive (erythroid-specific) factors binding to the
enhancer. We have previously shown (Ciana et al.,
1998) that two of the three potential GATA-factor
binding sites present in the HS2 enhancer fragment
(positions 913 and 940 referred to as I and II,
respectively) (Figure 1a) were protected in DMS
footprint assays in vivo and showed DNase I hyper-
sensitive cutting in vitro. A third potential GATA-site
(III, position 990) was protected only in in vitro
footprint assays. Using electrophoretic mobility shift
assays (EMSA), we also showed that the GATA-1
protein present in HD3 cells binds to GATA-site I.
Transient transfection assays confirmed that this
GATA-element was required for the HS2 enhancer
activity.
To elucidate the function of the two other GATA-
sites, we introduced mutations in these sites in the M1-
HS2-tk context i.e. in a configuration in which the
contribution of the GATA-sites can be monitored. In
transient transfection assays in HD3 cells, mutation of
either of the GATA-sites I or II (GI-M1-HS2 and GII-
M1-HS2, respectively) abolished enhancer activity
(Figure 4). Similar results were obtained in K562 and
MEL cells (data not shown). In contrast, mutation of
the GATA-site III (GIII-M1-HS2) resulted only in a
moderate reduction of the enhancer activity. These
results are in accordance with the deletion analysis
(Figure 2) showing that DNA sequences downstream
of the VRE do not significantly contribute to the
overall activity of the enhancer. In conclusion, the HS2
enhancer activity is strongly dependent on the two
adjacent GATA-factor binding sites (I and II) located
upstream of the VRE, suggesting that v-ErbA quenches
the positive transcriptional activity of factors (possibly
GATA-proteins) bound to these GATA-sites.
HS2 contains multiple half-sites
We have previously shown that v-ErbA binds to the
VRE as a heterodimer with RXR (Ciana et al., 1998).
The HS2-VRE deviates from a canonical TRE element
in the second half-site, an AGGgCt sequence rather
than AGGTCA (Figure 1a). Closer inspection of the
HS2 sequence revealed additional potential nuclear
receptor half-sites. Particularly, the non-consensus
half-site (position 949 – 954) located six base-pairs
upstream of the VRE together with the first half-site
of the VRE forms an everted repeat (ER) spaced by
six nucleotides (Figure 1a). ER6-type elements, such
Figure 3 The HS2 enhancer activity is erythroid-specific. Transient transfection assays with the indicated tk reporter constructs in
various cell lines as shown. The values represent the mean value of the relative CAT activity of at least three experiments.
Transcriptional activity of tk-CAT construct is arbitrarily set to 1
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as the F2 from the chicken lysozyme promoter, have
been shown to be targets for v-ErbA regulation of
transcription (Baniahmad et al., 1990; Wahlstrom et
al., 1996; Subauste and Koenig, 1998). Therefore we
investigated the relative contribution of each of these
half-sites in the v-ErbA mediated transcriptional
repression via HS2 using mutagenesis analysis (Figure
5). Transient transfection assays of the resulting M2-
HS2-tk and M3-HS2-tk constructs in HD3 cells
revealed enhancement of HS2 transcription suggesting
that both the DR4 and the ER6 elements equally
contribute to repression of the enhancer activity.
Furthermore, we observed that the central consensus
half-site alone was sucient to confer repression
(twofold) (Figure 5), consistent with data from
Baniahmad et al. (1990). Thus, all three half-sites
contribute to the v-ErbA-mediated repression, but
only the central consensus half-site is critical.
VRE can act as a TRE
Given the altered DNA binding specificity of v-ErbA
due to the P-box mutation (Subauste and Koenig,
1995; Judelson and Privalsky, 1996; Wahlstrom et al.,
1996), it was not a priori granted that TR could bind to
the CA II-VRE and mediate T3-dependent activation.
We, therefore, performed EMSA experiments using the
VRE oligonucleotide and extracts from HD3 cells or
nuclear receptors expressed from vaccinia virus. As
shown in Figure 6a, RXR-TR eciently bound to the
VRE (lane 8) suggesting that this element may serve as
a TRE. Neither v-ErbA nor RXR alone bound
eciently to the VRE under these conditions (lanes
3 – 5), while their combination (lanes 6 and 7) led to
formation of a protein-DNA complex with mobility
similar if not identical to that obtained with HD3 cell
extracts (lane 2). The faster migrating complex (lanes 3,
4, 6 and 7) most likely represents a v-ErbA monomer
bound to the VRE.
To measure the relative anities of RXR-v-ErbA
and RXR-TR for the VRE, o-rate experiments were
performed. Addition of unlabelled VRE probe as a
competitor led to the immediate disappearance of the
RXR-v-ErbA complex, whereas RXR-TR was detect-
able up to 4 minutes after addition of the competitor
(Figure 6b and data not shown). The t1/2 for the RXR-
v-ErbA complex on the VRE is in the range of seconds
while that for RXR-TR is in the range of minutes,
showing that the anity of RXR-v-ErbA for the HS2-
VRE is significantly lower than that of RXR-TR. A
gag-TRa receptor fusion (termed V3) expressed in the
HD3V3 cells (Disela et al., 1991) appeared to bind to
the HS2-VRE in conjunction with endogenous RXR
with kinetics similar to that of recombinant RXR-TR
(data not shown). These observations suggest that the
dierential binding behaviour of RXR-v-ErbA and
RXR-TR was not due to an intrinsic dierence in
DNA binding characteristics between recombinant,
vaccinia expressed and ‘natural’ receptors. It should
be noted that the RXR-TR complex formed on the
MoMLV-TRE (DR4-type) or on a consensus DR4 is
more stable than on the VRE (Bugge et al., 1992 and
data not shown), emphasising that the VRE is not an
optimal binding site for RXR-TR.
To investigate whether the HS2-VRE can mediate
T3-induced activation, we performed transient transfec-
tion assays in HD3V3 cells in which the level of
expression of gag-TRa (V3) is comparable to that of v-
ErbA (Disela et al., 1991). Transfection of the HS2-tk
reporter construct in these cells yielded transcription
levels comparable to those obtained in HD3 cells,
thereby suggesting that HS2 enhancer activity can be
quenched by gag-TRa. Addition of T3 boosted the
level of transcription 4.5-fold, which is only 25% of the
activity obtained with M1-HS2-tk in these cells (Figure
6c and Ciana et al., 1998). The impaired ability of the
wild type HS2 enhancer to display full activity in
response to T3 is most likely due to the high levels of
Figure 4 GATA-factor binding sites are required for the HS2 enhancer activity. Transient transfection assays in HD3 cells with tk
reporters carrying the M1-HS2 fragment with mutations of the individual GATA-sites as shown on the left. The values represent the
mean value of the relative CAT activity of at least three experiments. Transcriptional activity of tk-CAT construct is arbitrarily set
to 1
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v-ErbA in HD3V3 cells opposing the activation by
ligand-bound RXR-V3.
To directly compare the function of the VRE with
that of a canonical TRE in the context of HS2
enhancer, we replaced the VRE with a consensus
DR4 element by changing the 3’ most half-site of the
VRE (position 971 – 976) into AGGTCA yielding
DR4-HS2. In HD3V3 cells and in the absence of
hormone, transcription of the DR4-HS2-tk construct
was repressed to levels similar to that obtained with
HS2-tk suggesting that unliganded v-ErbA and/or V3
quenches the enhancer activity via a DR4. Adminis-
tration of T3 resulted in elevated levels of activation as
compared to HS2-tk (seven- and 4.5-fold, respectively)
(Figure 6c). To further investigate the ability of the
VRE to mediate a T3-response, we tested the minimal
VRE sequence placed in front of the tk promoter in
HD3V3 cells (VRE-tk). T3-dependent transcriptional
activation of the VRE-tk was merely 1.7-fold, while of
the F2 element and of the well-characterised MoMLV-
TRE (Sap et al., 1989) was six- and eight-fold,
respectively (Figure 6c, Ciana et al., 1998 and data
not shown). In summary, these data show that thyroid
hormone responsiveness can be mediated by the VRE
in the HS2 context. DR4, however, is more potent
since it nearly restores enhancer activity as defined by
the M1-HS2. Secondly, the VRE by itself possess very
little activation potential in cells that co-express v-
ErbA and gag-TRa.
v-ErbA and gag-TRa act differently to instigate
repression via the HS2 enhancer
Unliganded TR and v-ErbA are thought to repress
transcription of T3-regulated genes. Support for this
model is provided by experiments using the F2 element
from the chicken lysozyme gene promoter; transcrip-
tion of the F2 element is repressed 6 – 7-fold as
compared to tk alone in HD3 cells (Baniahmad et
al., 1992; Ciana et al., 1998 and Figure 3). We have so
far shown that the wild type HS2 enhancer is ‘neutral’,
i.e. it neither enhances nor represses transcription from
the homologous or from a heterologous promoter in
HD3 cells. This suggests that positive and negative
factors regulating its activity are in balance. To
investigate whether v-ErbA could actively repress the
transcriptional activity of the heterologous tk promoter
we mutated GATA-sites I and II within the wild type
HS2 enhancer so that the negative transcriptional
activity of v-ErbA would prevail (Figure 7a). Surpris-
ingly, transfection experiments in HD3 cells showed
that mutation of these GATA-sites (GI-HS2-tk and
GII-HS2-tk reporters) did not reduce transcription
significantly below that of the enhancerless tk promoter
(less than twofold) (Figure 7a). These data suggest that
in HD3 cells v-ErbA does not eciently, if at all,
repress the transcriptional activity intrinsic to the
heterologous tk promoter.
To test whether the incapacity of v-ErbA to convey
transcriptional repression to the linked tk promoter
was an intrinsic property of v-ErbA and/or dictated
by the VRE element, similar experiments were
performed in HD3V3 cells that express equivalent
levels of gag-TRa (V3) and v-ErbA. In HD3V3 cells,
the levels of transcription of GI-HS2-tk and GII-HS2-
tk were strongly repressed as compared to HS2-tk and
more importantly to tk alone (six- and 3.5-fold,
respectively) (Figure 7a). An even more pronounced
eect was obtained when a DR4-HS2 derivative
carrying a mutation in the GATA-site I was tested.
Figure 5 The HS2 enhancer contains multiple half-sites that can mediate repression by v-ErbA. Transient transfection assays in
HD3 cells with tk reporters containing mutations of the indicated potential half-sites (see Figure 1a for sequence). The values
represent the mean value of the relative CAT activity of at least three experiments. Transcription is expressed relative to tk promoter
alone
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The GI-DR4-HS2-tk reporter yielded a 10-fold
repression of transcription as compared to tk alone
in HD3V3 cells whereas the repression was less than
twofold in HD3 cells. Finally, in HD3 cells the
minimal HS2-VRE element (VRE-tk) yielded 1.3-fold
repression of transcription as compared to tk whereas
in HD3V3 cells the repression was up to fivefold.
Taken together these results show that v-ErbA in
contrast to gag-TRa is unable to convey repression to
the tk promoter when bound to the HS2-VRE. This
dierential activity is dictated by both the HS2
context and the VRE since transcription of the F2-
tk is equally repressed in both cell lines (Figure 7a).
Taken together, our data indicate that the ability of
the v-ErbA oncoprotein to repress is not equivalent to
that of unliganded gag-TRa.
Discussion
In this study we have continued to probe the function
of the leukemia inducing oncoprotein, v-ErbA, in the
control of transcriptional repression. Our detailed
analysis of the previously identified regulatory region
Figure 6 Liganded TR binds to and activates transcription from the HS2-VRE. (a) A gel mobility shift assay of 32P-labelled
synthetic oligonucleotide containing the VRE sequence using HD3 cell-extract or vaccinia-expressed receptor proteins, as indicated.
(b) O-rate assay performed with the same probe as in a and either HD3 cell-extract or vaccinia-expressed RXR-TR. Lane 1: free
probe; lane 2: VRE probe plus HD3 cell-extract; lanes 3 – 7: as in lane 2 plus 1000-fold of unlabelled VRE probe added as
competitor, with aliquots loaded on the gel at the indicated time points; lane 8: VRE probe plus vaccinia-expressed RXR-TR; lane
9 – 13: as in lane 8 plus unlabeled VRE probe as competitor with aliquots loaded on the gel at the indicated time points. (c)
Transient transfection assays in HD3V3 cells, expressing gag-TRa and v-ErbA, with the indicated tk reporter constructs. Black bars
denote relative CAT activities in the absence of hormone while hatched bars represent CAT values in the presence of T3.
Transcription is arbitrarily set to 1 for the to tk promoter alone in the absence of hormone
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in the erythroid stage-specific CA II gene (Ciana et al.,
1998) now provides a more precise model for the v-
ErbA-mediated repression. Firstly, we have shown that
the regulatory region of the CA II gene located in the
second intron, termed HS2, is a true enhancer that can
activate transcription independently of its position and
orientation relative to the promoter. The apparent
erythroid-specific activity of the enhancer in primary
erythroid progenitors as well as in other erythroid cells
appears to be dictated primarily by two adjacent
GATA-factor binding sites. Since both v-ErbA and
unliganded TR can eciently quench the activity of the
HS2 enhancer it appears that they both interfere with
the positive function of the erythroid GATA-factors.
Secondly, we have shown that the HS2 enhancer can
convey T3-mediated activation to a heterologous or
CA II promoter (Figure 6c and data not shown),
providing additional evidence for the role of T3 in the
activation of CA II transcription (Disela et al., 1991).
Thirdly, we have provided evidence that v-ErbA bound
to VRE, in contrast to unliganded TR, is impaired in
repressing the tk promoter.
Mutation and deletion analyses (Figures 3 and 4)
showed that the HS2 enhancer activity is greatly
dependent on two GATA-factor binding sites and that
v-ErbA when bound to the VRE can quench their
positive transcriptional activity. Interference of nuclear
receptor superfamily members with the function of
GATA-factors appears to be a recurring theme. For
example, the promoter of the slow myosin heavy chain
(MyHC) 3 gene contains one GATA-site and one
Vitamin D3 responsive element (VDRE). While
GATA-factors enhance the transcriptional activity of
the MyHC 3 promoter, VDR binding leads to
transcriptional repression in ventricular cardiomyocytes
(Wang et al., 1998). Moreover, liganded glucocorticoid
receptor (GR) has been shown to inhibit the function
of GATA-1 protein on the promoters of the b-major
and b-minor globin genes, most probably via a direct
interaction between GATA-1 and GR (Chang et al.,
1993). In pilot immunoprecipitation experiments, we
did not observe a direct interaction between GATA-
factors and v-ErbA, whereas the interaction between v-
ErbA and NCoR could readily be detected (GG
Figure 7 v-ErbA, unlike unliganded gag-TRa, cannot repress the transcriptional activity intrinsic to the tk promoter, when bound
to the HS2-VRE. (a) Transient transfection assays in HD3 cells (left) and in HD3V3 cells (right) with the indicated tk reporters. The
values represent the mean value of the relative CAT activity of at least three experiments. Transcription is expressed relative to tk
promoter alone for both cell lines. (b) Proposed model whereby unliganded gag-TRa can both quench the HS2 enhancer and the
transcription from tk promoter whereas the v-ErbA oncoprotein can only quench the activity of the enhancer
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Braliou and HG Stunnenberg unpublished observa-
tions).
The presence of enhancers in introns, regulating
transcription of tissue-specific genes, such as the HS2
from the CA II gene is not uncommon. Examples in
the hematopoietic system are the 3’ enhancer of the
chicken adult b-globin and the intronic immunoglobin
enhancer (Em) (Emerson et al., 1987; Jenuwein et al.,
1997). The 3’ intronic enhancer of the chicken adult b-
globin gene binds GATA-factors that could co-operate
with GATA-factors bound to a site proximal to the
TATA box to instigate transcription (Emerson et al.,
1987). We speculate that a similar mechanism may be
in place for the CA II locus since the CA II promoter
contains a GATA-motif. Our findings that HS2 can
enhance transcription from its own CA II promoter
more eciently compared to the heterologous tk
promoter, is in line with this model. Further investiga-
tions are required to address the nature of the
interference of v-ErbA with GATA-factors activity on
the CAII-HS2 enhancer.
Using normal, untransformed chicken erythroid
progenitors (T2ECs) (Gandrillon et al., 1999), HD3,
MEL and K562 cells as well as non-erythroid CEF
and L cells, we have shown that the HS2 enhancer
activity is erythroid-specific (Figure 3). The erythroid-
specific GATA-factors appear to govern the tran-
scriptional activity of the enhancer (Figure 4 and
data not shown). It is also evident that v-ErbA
accounts for the repression of HS2 enhancer in HD3.
This notion is further corroborated by the observa-
tion that cotransfection of v-ErbA in both MEL and
K562 cells diminished the transcriptional activity of
HS2 (data not shown). The variation in the
transcriptional activities as obtained with HS2, M1-
HS2 and HS2(883 – 958) is probable due to dier-
ences in the concentration of transcription factors
present at the dierent stages of erythroid dierentia-
tion in which the HD3, MEL, K562 cells and T2ECs
are arrested. The higher activity of the HS2(883 – 958)
enhancer as compared to HS2 and M1-HS2 in
T2ECs can be taken as evidence for the presence of
a cellular repressor in early erythroid progenitors. It
is tempting to speculate that the v-ErbA oncoprotein
fulfills the role of the cellular repressor in trans-
formed HD3 cells in repressing the CA II and other
targets.
In previous studies we and others showed that TRa
is likely to be involved in erythroid dierentiation
(Disela et al., 1991; Schroeder et al., 1992; Gandrillon
et al., 1994). We showed that liganded TRa plays a role
in CA II activation presumably by increasing the
accessibility of the HS2 (Ciana et al., 1998). The
notion that v-ErbA occludes liganded TR from its
binding site is supported by the fact that substitution
of the VRE with a canonical DR4, a better binding site
for TR, potentiates the T3 response (Figure 6c).
Therefore, the sequence composition of the VRE is
critical for the eciency of the occlusion since v-ErbA
occludes liganded gag-TRa more eciently on the
VRE than on the DR4.
As mentioned before, v-ErbA prevents the HS2
enhancer by quenching the GATA-factors activity, a
function that is exerted locally within the HS2 region.
Gag-TRa can also quench HS2 activity (Figure 7a,
compare HS2-tk in HD3 and HD3V3 cells) consistent
with the observation that in erythroid cells over-
expressing gag-TRa CA II is repressed in the absence
of T3 (Disela et al., 1991; Bauer et al., 1998). However
v-ErbA, unlike unliganded gag-TRa, was unable to
actively repress transcription from the heterologous tk
promoter when bound to the HS2-VRE (Figure 7a).
Unliganded TRa and TRb have been reported to
interfere with the preinitiation complex (PIC) assembly
to actively repress transcription. It has been shown that
TR directly interacts with TFIIB (Baniahmad et al.,
1993; Fondell et al., 1993, 1996) while v-ErbA is
impaired in such an interaction (Urnov et al., 2000).
We speculate that v-ErbA is unable to interact with
TFIIB in the context of the HS2-VRE, and thus
cannot interfere with factors governing the basal
transcription of the tk promoter.
Recent data have implicated helix 12 (H12) of the
receptors LBD in corepressor binding (Zhang et al.,
1999; Renaud et al., 2000). Given that v-ErbA lacks an
intact H12, it is possible that distinct binding anities
for corepressors might account at least partially for the
dierential v-ErbA and TR repression capacity. Our
finding that v-ErbA and TR show distinct repression
activities on the VRE but not on the F2 element are
consistent with observations suggesting repression and
corepressor release to be dependent on the architecture
of TREs (Olson et al., 1998; Wahlstrom et al., 1998).
Extrapolation of our observations should be done with
great care, because the data presented here is based on
transient transfection assays where the introduced
DNAs adopt an abnormal nucleosomal structure that
diers from that of endogenous genes (Archer et al.,
1992; Cereghini and Yaniv, 1984; Innis and Scott,
1983; Jeong and Stein, 1994; Reeves et al., 1985; Van
Lint et al., 1996). It is throughout possible that v-ErbA
utilises additional mechanisms to repress transcription
in the context of chromatin. Additional in vivo and in
vitro experiments are needed to unravel how v-ErbA
functions within chromatin to shed light on the
correlation between repression by v-ErbA and its
oncogenicity.
In conclusion, v-ErbA appears to regulate transcrip-
tion in at least three ways: firstly, by quenching the
activity of GATA-factors bound to the HS2, secondly,
by occluding liganded TRa and thirdly by interfering
with the repression function of unliganded TRa (Figure
7b). Similar mechanisms might be in place for other
erythroid v-ErbA target genes. We propose that v-
ErbA, apart from the already known ability to occlude
liganded TR, can antagonise the function of un-
liganded TRa as well when bound to the HS2-VRE,
thus preventing the full silencing function of TRa.
Altogether, our data fit within an increasing amount of
reports demonstrating the existence of subtle dier-
ences between the unliganded TRa and the v-ErbA
oncoprotein, in terms of subcellular localization
Transcriptional repression by v-ErbA
GG Braliou et al
784
Oncogene
(Boucher et al., 1988), competition for a transcriptional
repressor (Rascle et al., 1994), binding of cofactors
(Barettino et al., 1993), and DNA binding specificity
(Chen et al., 1993; Subauste and Koenig, 1995;
Judelson and Privlasky, 1996). It is quite possible that
these functional dierences in the repressive, unli-
ganded modes of v-ErbA and gag-TRa may contribute
to v-ErbA oncogenic activity. Nevertheless, the precise
contribution of those dierences to the transforming
ability of v-ErbA will await the yet-to-come functional
identification of the transformation-relevant target
genes of v-ErbA.
Studies on v-ErbA function are moving our knowl-
edge forward to unravelling the connections between
transcriptional repression and oncogenicity. Applying
this knowledge will certainly provide novel insights into
the molecular mechanisms controlling normal and
abnormal erythroid dierentiation.
Materials and methods
Cell culture
The derivatives of the AEV-transformed cell line HD, HD3-
EpoR and HD3-V3, expressing the murine erythropoietin
receptor or a gag-chicken TRa fusion, respectively, were
grown in CFU-E medium (Dolznig et al., 1995). Before T3
treatment, HD3-V3 cells were grown for 48 h in medium
containing stripped serum using the anion-exchange resin AG
1-X8 (BIORAD). Chicken embryo fibroblasts (CEF) were
grown in Iscoves’ medium (Gibco –BRL) supplemented with
8% fetal calf serum, 2% chicken serum and antibiotics. MEL
cells were grown in DMEM (Gibco –BRL) supplemented
with 10% fetal calf serum and non-essential amino-acids
(Philipsen et al., 1990). L cells and were grown in DMEM
(Gibco –BRL) supplemented with 10% fetal calf serum
(Baniahmad et al., 1992). K562 cells were grown in RPMI-
1640 supplemented with 10% fetal calf serum (Geijtenbeek et
al., 2000). T2ECs were grown in LM1 medium as previously
described (Gandrillon et al., 1999).
Transient transfection assays
HD3-EpoR, HD3-V3 and K562 cells were transfected using
the DEAE-dextran transfection procedure as previously
described (Choi and Engel, 1988). In a typical experiment,
107 or 56106 for K562) cells were transfected with 5 (or 10)
mg of reporter construct together with 1 mg of EF1a-Luc as
internal control, and harvested after 48 h. One hundred and
fifty nM T3 was added to HD3-V3 transfected cells for the
last 24 h where indicated. CAT and luciferase activities were
measured as described previously (Barettino et al., 1993).
MEL cells were transfected by electroporation as described
(Philipsen et al., 1990). Briefly 26107 cells were incubated on
ice for 10’ with 20 mg of reporter construct together with 5 mg
of EF1a-Luc as internal control and 15 mg of empty pSG7
vector to keep the same amount of transfected DNA in all
samples. Subsequently, the cells were electroporated in a
BIORAD gene pulser at 960 mF and 280 V and after 10’
incubation on ice were plated in 10 ml of complete medium.
After 48 h, the cells were harvested for measurement of CAT
and luciferase activities.
CEF and L cells were transfected with the calcium
phosphate method as described (Berkenstam et al., 1992;
Barettino et al., 1993). Briefly, 36105 cells were transfected
with 5 mg of reporter construct along with 1 mg of EF1a-Luc
as internal control and 5 mg of empty pSG7 vector. After
16 h the cells were washed with phosphate buer saline (PBS)
and harvested after 24 h for measurement of CAT and
luciferase activities.
T2ECs were transfected with 5 mg of reporter construct
along with 2 mg of EF1a-Luc using LipofectamineTM reagent,
as will be described in details elsewhere (M Deguillien, M
Morinie`re, S Dazy, O Gandrillon and F Baklouti; manuscript
in preparation). After 48 h, the cells were harvested for
measurement of CAT and luciferase activities.
Oligonucleotides used for gel retardation assays and for cloning
in pBLCAT2 vector
Oligonucleotides used for gel retardation. Coding strand:
VRE: 5’-TCGACCCAGCAAGGTCACAGCAGGGCTTTT-
TTTC-3’, Non coding strand: VRE: 5’-TCGAGAAAAAAA-
GCCCTGCTGTGACCTTGCTGGG-3’. Oligonucleotides used
for mutagenesis: pBL5’: 5’-TCCCAGTCACGACGTTGT-
AAA-3’ in pBLCAT2; pBL3’: 5’- GTTCGAATTCGCCAAT-
GACAA-3’ pBLCAT2; mutagenesis-VRE-M1: 5’-CCCTG-
CTGTGAAATTGCTG-3’; mutagenesis-VRE-M2: 5’-AAAG-
CAATGCTGTGACCTTG-3’ mutagenesis-VRE-M3: 5’-TTG-
CTGGTTTACTAGCCTGATAAGG-3’; mutagenesis-GI-
GATA: 5’-GTTCCAGAGATTTAGGTCAG-3’; mutagen-
esis-GII-GATA: 5’-GGACTAGCCTTGTAAGGTA-3’; mu-
tagenesis-GIII-GATA: 5’-CTACGTAATTGGTAAATCATA-
3’ mutagenesis-VRE-DR4: 5’-CTCATAAGAAAAAATGAC-
CTGCTGT-3’.
Oligonucleotides used for cloning: Upper strand. M1-927 –
945: 5’-CCCAAGCTTATCCTTGCTACCTTATCAG-3’ (HindIII
site underlined) M1-951 – 971: 5’-CCCAAGCTTTCCCCC-
AGCAATTTCACAGCA-3’ (HindIII site underlined) 979 –
998: 5’-GCTCTAGAGCTTTCTTATGAGATACCAA-3’ (XbaI
site underlined); 1019 – 1041: 5’-GCTCTAGAGCTCATTA-
CAGATGTTTTTTGC-3’ (XbaI site underlined); CAII
upper: 5’-CTTTGATCTGCGCCTCCA-3’.
Lower strand. 1021 – 1004: 5’-GCTCTAGAGCTTCACCA-
AAAGAACCTA-3’ (XbaI site underlined) M1-983 – 966: 5’-
GCTCTAGAGCGAGAAAAAAAGCCCTGCTGT-3’ (XbaI
site underlined) 958 – 938: 5’-GCTCTAGATGGGGGACTA-
GCCTGATAAG-3’ (XbaI site underlined) CAII lower: 5’-
CGGGATCCCGCCAGTGATGGGACCTGGTG-3’ (BamHI
site underlined).
Gel retardation assay
Twenty pmoles of labelled VRE-oligonucleotide were in-
cubated with HD3 protein extract (40 mg) or vaccinia-virus
expressed v-ErbA, TR and RXR proteins for 20’ on ice (de
Magistris and Stunnenberg, 1988; Stunnenberg et al., 1988).
Binding was performed as described (Ciana et al., 1998). O-
rate competition was performed by adding a 100- or 1000-
fold molar excess of unlabelled VRE-oligonucleotide and
aliquots were applied on pre-cooled and pre-run 0.56TBE,
5% polyacrylamide gels at the indicated time points.
Plasmids
A RsaI/RsaI fragment of 288 bp spanning the HS2 was
inserted into EcoRV site of pBlueScript and subsequently
subcloned into SalI/BamHI sites of pBLCAT2 (Lucknow and
Schutz, 1987), yielded plasmid HS2(883 – 1175)-tk. M1(883 –
1175)-tk was generated from HS2(883 – 1175)-tk by oligonu-
cleotide-directed site-specific mutagenesis (Seraphin and
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Kandels-Lewis, 1996) using the oligonucleotides pBL5’ and
pBL3’ and the mutagenesis oligonucleotide M1-VRE. The
HS2-tk construct was generated from HS2(883 – 1175)-tk by
PCR amplification using primers pBL5’ and 1021-1004,
digested with SalI/XbaI and inserted into SalI/XbaI sites of
pBLCAT2. M1-HS2-tk was generated from HS2-tk by
oligonucleotide-directed site-specific mutagenesis using the
oligonucleotide M1-VRE.
M1(927 – 1175)-tk and M1(951 – 1175)-tk constructs were
generated by PCR amplification of M1(883 – 1175)-tk using
primers 927 – 945 and M1-951 – 971, respectively, along with
pBL3’, digested with HindIII/XbaI and inserted into HindIII/
XbaI site of pBLCAT2. HS2(979 – 1175)-tk construct was
generated by PCR amplification of HS2(883 – 1175)-tk using
primers 979 – 998 and pBL3’, digested with XbaI and inserted
into XbaI site of pBLCAT2. PCR amplification of M1-HS2-
tk with primers pBL5’ and M1-983 – 966 or 958 – 938,
digesting with HindIII/XbaI and subsequent cloning into
HindIII/XbaI site of pBLCAT2, yielded plasmids M1(883 –
983)-tk and HS2(883 – 958)-tk respectively. Annealing of
primers VRE-upper and VRE lower and ligation with
pBLCAT2 digested with SalI yielded plasmid VRE-tk. F2-
tk plasmid was a kind gift from Baniahmad et al. (1992).
A CA II promoter fragment was PCR amplified using
primers CAII-upper and CAII-lower (has a mutation in the
ATG of CA II), digested with ApaI, filled in with Klenow
and digested with BamHI. The resulting 263 bp promoter
fragment, inserted into XbaI, filled in with Klenow and
BamHI sites of pBLCAT3, yielded construct CA II. Digest-
ing the CA II with SalI, filling in with Klenow and ligating
with an excised insert from M1-HS2 with SalI/XbaI and filled
in with Klenow, yielded plasmids M1-HS2-CAII(+) and M1-
HS2-CAII(7). For the generation of CAII-M1-HS2(+)/(7)
the M1-HS2 insert was excised from M1-HS2-tk construct
with SalI/XbaI filled in with Klenow, and ligated with CAII
plasmid digested with SmaI.
M2-HS2-tk and M3-HS2-tk were generated from HS2-tk
by oligonucleotide-directed site-specific mutagenesis using the
mutagenesis oligonucleotides M2-VRE and M3-VRE respec-
tively. M1M3-HS2-tk and M2M3-HS2-tk were generated
from M1-HS2-tk and M2-HS2-tk using the M3-VRE
oligonucleotide.
M1-HS2 constructs carrying mutations of the GATA-sites
were generated from M1-HS2-tk and mutagenesis oligonu-
cleotides GI-GATA, GII-GATA and GIII-GATA. Likewise,
the GI- and GII-HS2-tk constructs were created from the
HS2-tk. DR4-HS2-tk was constructed with the mutagenesis
oligonucleotide VRE-DR4 from HS2-tk construct and from
this, using the mutagenesis oligonucleotide GI-GATA, the
GI-DR4-HS2-tk plasmid was generated. All constructs were
checked using sequencing analysis.
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